Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Methods for the In Silico Prediction of Novel Inhibitors against Kirsten Rat Sarcoma G12D Cancer Drug Target
Keywords:
KRAS G12D, machine learning-based virtual screening, molecular docking, MD simulationsAbstract
The vast majority of human cancers are caused by mutations in the Kirsten rat sarcoma (KRAS) viral proto-oncogene. A significant portion—approximately 30%—of lung, pancreas, and colon cancers in humans are triggered by oncogenic KRAS mutations. An appealing therapeutic target is one of the most common mutant KRAS G12D mutations, which causes pancreatic cancer. There are currently no medications that have been authorised for use by the FDA that target the KRAS G12D mutation. In light of this, research
towards a viable treatment for KRAS G12D must proceed. Discovering new medications is a laborious and costly procedure. Alternatively, in silico drug development approaches save time and money. In this study, we used ML methods including K-nearest neighbour (KNN), support vector machine (SVM), and random forest (RF) to find novel inhibitors for the KRAS G12D mutant. Based on the predictions, 82 hits were active against the KRAS G12D mutant. Docking the active hits into the KRAS G12D mutant's active site was the process. In addition, the stability of the compounds with strong docking scores was assessed by running 200 ns MD simulations on the top two complexes and the reference complex (MRTX-1133). As compared to the conventional compound, the top two hits demonstrated great stability. In comparison to the gold standard compound, the binding energies of the top two hits were respectable. Our discovered hits may aid in the fight against cancer by blocking the KRAS G12D mutation. We are unaware of any previous research that has used molecular docking, molecular dynamics simulation, virtual screening based on machine learning, and the KRAS G12D mutant to find potential novel inhibitors.
References
Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17–48. [CrossRef] [PubMed]
Parkin, D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 2006, 118, 3030–3044. [CrossRef] [PubMed]
Almasmoum, H. Characterization of Mucin 2 Expression in Colorectal Cancer with and without Chemotherapies. Vivo Vitr. Study. JUQUMS 2021, 7, 18–22. [CrossRef]
Meng, M.; Zhong, K.; Jiang, T.; Liu, Z.; Kwan, H.Y.; Su, T. The c urrent understanding on the impact of KRAS on colorectal cancer. Biomed. Pharmacother. 2021, 140, 111717. [CrossRef] [PubMed]
Chen, J.; Zhang, S.; Wang, W.; Pang, L.; Zhang, Q.; Liu, X. Mutation-induced impacts on the switch transformations of the GDP-and GTP-bound K-ras: Insights from multiple replica Gaussian accelerated molecular dynamics and free energy analysis. J. Chem. Inf. Model. 2021, 61, 1954–1969. [CrossRef] [PubMed]
Favazza, L.A.; Parseghian, C.M.; Kaya, C.; Nikiforova, M.N.; Roy, S.; Wald, A.I.; Landau, M.S.; Proksell, S.S.; Dueker, J.M.; Johnston, E.R. KRAS amplification in metastatic colon cancer is associated with a history of inflammatory bowel disease and may confer resistance to anti-EGFR therapy. Mod. Pathol. 2020, 33, 1832–1843. [CrossRef] [PubMed]
Chakrabarti, M.; Jang, H.; Nussinov, R. Comparison of the conformations of KRAS isoforms, K-Ras4A and K-Ras4B, points to similarities and significant differences. J. Phys. Chem. B 2016, 120, 667–679. [CrossRef]
Cox, A.D.; Der, C.J. Ras history: The saga continues. Small GTPases 2010, 1, 2–27. [CrossRef]
Lam, K.K.; Wong, S.H.; Cheah, P.Y. Targeting the ‘Undruggable’Driver Protein, KRAS, in Epithelial Cancers: Current Perspective. Cells 2023, 12, 631. [CrossRef]
Shen, H.; Lundy, J.; Strickland, A.H.; Harris, M.; Swan, M.; Desmond, C.; Jenkins, B.J.; Croagh, D. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? Cells 2022, 11, 3175. [CrossRef] [PubMed]
Hofmann, M.H.; Gerlach, D.; Misale, S.; Petronczki, M.; Kraut, N. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022, 12, 924–937. [CrossRef] [PubMed]
Nagasaka, M.; Li, Y.; Sukari, A.; Ou, S.-H.I.; Al-Hallak, M.N.; Azmi, A.S. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat. Rev. 2020, 84, 101974. [CrossRef]
Kargbo, R.B. Targeting KRASG12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers. ACS Med. Chem. Lett. 2023, 14, 1041–1042. [CrossRef] [PubMed]
Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade, R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today 2021, 26, 80. [CrossRef]
Noor, F.; Noor, A.; Ishaq, A.R.; Farzeen, I.; Saleem, M.H.; Ghaffar, K.; Aslam, M.F.; Aslam, S.; Chen, J.-T. Recent advances in diagnostic and therapeutic approaches for breast cancer: A comprehensive review. Curr. Pharm. Des. 2021, 27, 2344–2365. [CrossRef] [PubMed]
Noor, F.; Tahir ul Qamar, M.; Ashfaq, U.A.; Albutti, A.; Alwashmi, A.S.; Aljasir, M.A. Network pharmacology approach for medicinal plants: Review and assessment. Pharmaceuticals 2022, 15, 572. [CrossRef]
Floresta, G.; Zagni, C.; Gentile, D.; Patamia, V.; Rescifina, A. Artificial intelligence technologies for COVID-19 de novo drug design. Int. J. Mol. Sci. 2022, 23, 3261. [CrossRef] [PubMed]
Sadaqat, M.; Qasim, M.; ul Qamar, M.T.; Masoud, M.S.; Ashfaq, U.A.; Noor, F.; Fatima, K.; Allemailem, K.S.; Alrumaihi, F.; Almatroudi, A. Advanced network pharmacology study reveals multi-pathway and multi-gene regulatory molecular mechanism of Bacopa monnieri in liver cancer based on data mining, molecular modeling, and microarray data analysis. Comput. Biol. Med. 2023, 161, 107059. [CrossRef]
Yang, J.; Cai, Y.; Zhao, K.; Xie, H.; Chen, X. Concepts and applications of chemical fingerprint for hit and lead screening. Drug Discov. Today 2022, 27, 103356. [CrossRef]
Tang, D.; Kang, R. Glimmers of hope for targeting oncogenic KRAS-G12D. Cancer Gene Ther. 2023, 30, 391–393. [CrossRef] [PubMed]
Lin, X.; Yang, F.; Zhou, L.; Yin, P.; Kong, H.; Xing, W.; Lu, X.; Jia, L.; Wang, Q.; Xu, G. A support vector machine-recursive feature elimination feature selection method based on artificial contrast variables and mutual information. J. Chromatogr. B 2012, 910, 149–155. [CrossRef] [PubMed]
Samad, A.; Ajmal, A.; Mahmood, A.; Khurshid, B.; Li, P.; Jan, S.M.; Rehman, A.U.; He, P.; Abdalla, A.N.; Umair, M. Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD simulation. Front. Mol. Biosci. 2023, 10, 1060076. [CrossRef]
Ajmal, A.; Ali, Y.; Khan, A.; Wadood, A.; Rehman, A.U. Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling. J. Biomol. Struct. Dyn. 2023, 41, 8866–8875. [CrossRef] [PubMed]
Khan, A.; Randhawa, A.W.; Balouch, A.R.; Mukhtar, N.; Sayaf, A.M.; Suleman, M.; Khan, T.; Ali, S.; Ali, S.S.; Wang, Y. Blocking key mutated hotspot residues in the RBD of the omicron variant (B. 1.1. 529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches. RSC Adv. 2022, 12, 7318–7327. [CrossRef] [PubMed]
Mizrahi, J.D.; Surana, R.; Valle, J.W.; Shroff, R.T. Pancreatic cancer. Lancet 2020, 395, 2008–2020. [CrossRef] [PubMed]
Rahib, L.; Wehner, M.R.; Matrisian, L.M.; Nead, K.T. Estimated projection of US cancer incidence and death to 2040. JAMA Netw. Open 2021, 4, e214708. [CrossRef] [PubMed]
Moore, A.R.; Rosenberg, S.C.; McCormick, F.; Malek, S. RAS-targeted therapies: Is the undruggable drugged? Nat. Rev. Drug Discov. 2020, 19, 533–552. [CrossRef] [PubMed]
Akkapeddi, P.; Hattori, T.; Khan, I.; Glasser, E.; Koide, A.; Ketavarapu, G.; Whaby, M.; Zuberi, M.; Teng, K.W.; Lefler, J. Exploring switch II pocket conformation of KRAS (G12D) with mutant-selective monobody inhibitors. Proc. Natl. Acad. Sci. USA 2023, 120, e2302485120. [CrossRef]
Waters, A.M.; Der, C.J. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb. Perspect. Med. 2018, 8, a031435. [CrossRef]
Yousef, A.; Yousef, M.; Chowdhury, S.; Abdilleh, K.; Knafl, M.; Edelkamp, P.; Alfaro-Munoz, K.; Chacko, R.; Peterson, J.; Smaglo, B.G. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis. Oncol. 2024, 8, 27. [CrossRef] [PubMed]
Patel, L.; Shukla, T.; Huang, X.; Ussery, D.W.; Wang, S. Machine learning methods in drug discovery. Molecules 2020, 25, 5277. [CrossRef] [PubMed]
Sharma, G.; Shukla, R.; Singh, T.R. Identification of small molecules against the NMDAR: An insight from virtual screening, density functional theory, free energy landscape and molecular dynamics simulation-based findings. Netw. Model. Anal. Health Inform. Bioinform. 2022, 11, 31. [CrossRef]
Zhu, J.; Wu, Y.; Wang, M.; Li, K.; Xu, L.; Chen, Y.; Cai, Y.; Jin, J. Integrating machine learning-based virtual screening with multiple protein structures and bio-assay evaluation for discovery of novel GSK3β inhibitors. Front. Pharmacol. 2020, 11, 566058. [CrossRef]
Oyedele, A.-Q.K.; Owolabi, N.A.; Odunitan, T.T.; Christiana, A.A.; Jimoh, R.O.; Azeez, W.O.A.; Titilayo, M.B.-H.; Soares, A.S.; Adekola, A.T.; Abdulkareem, T.O. The discovery of some promising putative binders of KRAS G12D receptor using computer-aided drug discovery approach. Inform. Med. Unlocked 2023, 37, 101170. [CrossRef]
Wadood, A.; Ajmal, A.; Junaid, M.; Rehman, A.U.; Uddin, R.; Azam, S.S.; Khan, A.Z.; Ali, A. Machine learning-based virtual screening for STAT3 anticancer drug target. Curr. Pharm. Des. 2022, 28, 3023–3032. [CrossRef] [PubMed]
Sahoo, K.; Samal, A.K.; Pramanik, J.; Pani, S.K. Exploratory data analysis using Python. Int. J. Innov. Technol. Explor. Eng. 2019, 8, 4727–4735. [CrossRef]
Datta, R.; Das, D.; Das, S. Efficient lipophilicity prediction of molecules employing deep-learning models. Chemom. Intell. Lab. Syst. 2021, 213, 104309. [CrossRef]
Akbar, S.; Hayat, M.; Tahir, M.; Chong, K.T. cACP-2LFS: Classification of anticancer peptides using sequential discriminative model of KSAAP and two-level feature selection approach. IEEE Access 2020, 8, 131939–131948. [CrossRef]
Zhang, Z. Introduction to machine learning: K-nearest neighbors. Ann. Transl. Med. 2016, 4, 218. [CrossRef]
Di Stefano, M.; Galati, S.; Ortore, G.; Caligiuri, I.; Rizzolio, F.; Ceni, C.; Bertini, S.; Bononi, G.; Granchi, C.; Macchia, M. Machine learning-based virtual screening for the identification of CDK5 inhibitors. Int. J. Mol. Sci. 2022, 23, 10653. [CrossRef]
Ahmad, I.; Basheri, M.; Iqbal, M.J.; Rahim, A. Performance comparison of support vector machine, random forest, and extreme learning machine for intrusion detection. IEEE Access 2018, 6, 33789–33795. [CrossRef]
Halwani, A.A. Development of pharmaceutical nanomedicines: From the bench to the market. Pharmaceutics 2022, 14, 106. [CrossRef]
Denisko, D.; Hoffman, M.M. Classification and interaction in random forests. Proc. Natl. Acad. Sci. USA 2018, 115, 1690–1692. [CrossRef]
Akbar, S.; Rahman, A.U.; Hayat, M.; Sohail, M. cACP: Classifying anticancer peptides using discriminative intelligent model via Chou’s 5-step rules and general pseudo components. Chemom. Intell. Lab. Syst. 2020, 196, 103912. [CrossRef]
Jiao, Y.; Du, P. Performance measures in evaluating machine learning based bioinformatics predictors for classifications. Quant. Biol. 2016, 4, 320–330. [CrossRef]
Alotaibi, B.S.; Ajmal, A.; Hakami, M.A.; Mahmood, A.; Wadood, A.; Hu, J. New drug target identification in Vibrio vulnificus by subtractive genome analysis and their inhibitors through molecular docking and molecular dynamics simulations. Heliyon 2023, 9, e17650. [CrossRef] [PubMed]
Qazi, S.; Das, S.; Khuntia, B.K.; Sharma, V.; Sharma, S.; Sharma, G.; Raza, K. In silico molecular docking and molecular dynamic simulation analysis of phytochemicals from Indian foods as potential inhibitors of SARS-CoV-2 RdRp and 3CLpro. Nat. Prod. Commun. 2021, 16, 1934578X211031707. [CrossRef]
Ullah, H.; Nawaz, A.; Rahim, F.; Uddin, I.; Hussain, A.; Hayat, S.; Zada, H.; Khan, M.U.; Khan, M.S.; Ajmal, A. Synthesis, in vitro β-glucuronidase inhibitory potential and molecular docking study of benzimidazole analogues. Chem. Data Collect. 2023, 44, 100996. [CrossRef]
Ajmal, A.; Mahmood, A.; Hayat, C.; Hakami, M.A.; Alotaibi, B.S.; Umair, M.; Abdalla, A.N.; Li, P.; He, P.; Wadood, A. Computerassisted drug repurposing for thymidylate kinase drug target in monkeypox virus. Front. Cell. Infect. Microbiol. 2023, 13, 618. [CrossRef]
Muhammad, N.; Khan, R.; Seraj, F.; Khan, A.; Ullah, U.; Wadood, A.; Ajmal, A.; Ali, B.; Khan, K.M.; Nawaz, N.U.A. In vivo analgesic, anti-inflammatory and molecular docking studies of S-naproxen derivatives. Heliyon 2024, 10, e24267. [CrossRef] [PubMed]
He, Y.; Liu, K.; Cao, F.; Song, R.; Liu, J.; Zhang, Y.; Li, W.; Han, W. Using deep learning and molecular dynamics simulations to unravel the regulation mechanism of peptides as noncompetitive inhibitor of xanthine oxidase. Sci. Rep. 2024, 14, 174. [CrossRef] [PubMed]
Korlepara, D.B.; Vasavi, C.S.; Srivastava, R.; Pal, P.K.; Raza, S.H.; Kumar, V.; Pandit, S.; Nair, A.G.; Pandey, S.; Sharma, S.; et al. PLAS-20k: Extended Dataset of Protein-Ligand Affinities from MD Simulations for Machine Learning Applications. Sci. Data 2024, 11, 180. [CrossRef] [PubMed]
Khan, H.; Waqas, M.; Khurshid, B.; Ullah, N.; Khalid, A.; Abdalla, A.N.; Alamri, M.A.; Wadood, A. Investigating the role of Sterol C24-Methyl transferase mutation on drug resistance in leishmaniasis and identifying potential inhibitors. J. Biomol. Struct. Dyn. 2023, 1–14. [CrossRef] [PubMed]
